Cancer risks in first-degree relatives of CHEK2 mutation carriers: Effects of mutation type and cancer site in proband

British Journal of Cancer

Volumn 100, Issue 9, 2009, Pages 1508-1512

  Gronwald, J ^a   Cybulski, C ^a   Piesiak, W ^a   Suchy, J ^a   Huzarski, T ^a   Byrski, T ^a   Gorski, B ^a   Debniak, T ^a   Szwiec, M ^b   Wokolowczyk, D ^a   Matuszewski, M ^c   Sun, P ^d   Lubinski, J ^a   Narod, S A ^d  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Hospital   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; CHEK2; Colon cancer; Prostate cancer

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; COLON CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PEDIGREE ANALYSIS; POLAND; PRIORITY JOURNAL; PROSTATE CANCER; RELATIVE; BREAST TUMOR; COLON TUMOR; FAMILY; GENETICS; HETEROZYGOTE; INSTRUMENTATION; MUTATION; NEOPLASM; PROSTATE TUMOR;

BREAST NEOPLASMS; CARRIER STATE; COLONIC NEOPLASMS; FAMILY; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MUTATION; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 65549155934     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605038     Document Type: Article

References (17)

1. Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94: 1221-1226
2. Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10: 208
3. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet 74: 1175-1182
4. Cybulski C, Górski B, Huzarski T, ojæ B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, mañska A, mañska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, iñski J (2004a) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genetic 75: 1131-1135
5. Cybulski C, Gliniewicz B, Sikorski A, trok;adny J, Huzarski T, Gronwald J, Byrski T, Debniak T, Gorski B, Jakubowska A, Wokolorczyk D, Narod SA, Lubiñski J (2007c) Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 16: 572-576
6. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, Górski B, øorczyk D, jæ B, Narod SA, ñski J. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Clin Genet 2009; 75:72-78
7. Cybulski C, Huzarski T, Górski B, ojæ B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, strok;owocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, iñski J (2004b) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64: 2677-2679
8. Cybulski C, olorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, ojæ B, Jakubowska A, van de Wetering T, Narod SA, iñski J (2007a) A deletion in CHEK2 of 5395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 102: 119-122
9. Cybulski C, olorczyk D, strok;adny J, Kurzawski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Górski B, D Ecedil Bniak T, Narod SA, iñski J (2007b) Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 15: 237-241
10. Gronwald J, Huzarski T, Byrski B, Medrek K, Menkiszak J, Monteiro AN, Sun P, Lubinski J, Narod SA (2006) Cancer risks in first-degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet 43: 424-428
11. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66: 1259-1272
12. Narod SA, Lynch HT (2007) CHEK2 mutation and hereditary breast cancer. J Clin Oncol 25: 6-7
13. Risch HA, Narod SA (2003) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95: 73-74
14. Serrano-Fernández P, circ;bniak T, Górski B, Bogdanova N, Dörk T, Cybulski C, Huzarski T, Byrski T, Gronwald J, Øorczyk D, Narod SA, ñski J. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Res Treat 2008 [e-pub ahead of print]
15. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91: 1241-1247
16. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26000 patient cases and 27000 controls. J Clin Oncol 26: 542-548
17. Zhang S, Phelan CM, Zhang P, Rousseau F, Ghadirian P, Robidoux A, Foulkes W, Hamel N, McCready D, Trudeau M, Lynch H, Horsman D, De Matsuda ML, Aziz Z, Gomes M, Costa MM, Liede A, Poll A, Sun P, Narod SA (2008) Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res 68:2154-2157